齐多夫定与干扰素-α联合治疗的应用与研究进展  

Application and Research Progress of Zidovudine and Interferon-α Combination Therapy

作　　者：祝典 谭陈新 马广勇 

机构地区：[1]中国药科大学多靶标天然药物全国重点实验室,江苏 南京

出　　处：《生物医学》2025年第2期377-388,共12页Hans Journal of Biomedicine

摘　　要：干扰素-α (IFN-α)是一种具有抗病毒、抗肿瘤及免疫调节功能的细胞因子,而齐多夫定(AZT)则是首个获得批准的抗HIV逆转录酶抑制剂。两者的联合使用旨在通过协同作用增强抗病毒效果,但后续研究表明其疗效与毒性之间存在复杂的权衡关系。本文结合基础研究与临床数据,系统总结了齐多夫定的临床应用范围及其作用机制,干扰素-α的生物学功能及应用,以及齐多夫定与干扰素-α在不同疾病中的联合应用。此外,本文还探讨了齐多夫定与干扰素-α联合应用的潜在作用机制,以及相关争议与不足之处,并指出未来研究的重点方向。通过全面评述该联合治疗的科学价值与局限性,本文对齐多夫定与干扰素-α的联合应用展开深入探讨,阐明了其在抗病毒和抗肿瘤领域的重要价值,为后续联合治疗的研究方向提供新的思路。Interferon-alpha (IFN-α) is a multifunctional cytokine renowned for its antiviral, antitumor, and immunomodulatory properties, while Zidovudine (AZT) stands as the first approved reverse transcriptase inhibitor targeting HIV. The combined use of these two agents aims to amplify antiviral efficacy through synergistic interactions;however, subsequent research has revealed a complex interplay between therapeutic benefits and toxicological trade-offs. This article systematically synthesizes foundational research and clinical data to delineate the scope of Zidovudine’s clinical applications and its mechanisms of action, the biological functions and therapeutic uses of Interferon-alpha, as well as the combined application of Zidovudine and Interferon-alpha across various diseases. Furthermore, this paper explores the potential mechanisms underlying the combined use of Zidovudine and Interferon-alpha, addresses ongoing controversies and limitations, and identifies key directions for future research. By comprehensively reviewing the scientific value and limitations of this combined treatment, this pape

关 键 词：齐多夫定 干扰素-Α 联合应用 研究进展 

分 类 号：R978.7[医药卫生—药品]